Coagulogen-free clarified limulus amebocyte lysate

Patent metadata

Field	Value
Publication number	US-12359241-B2
Application number	US-202217737578-A
Country	US
Kind code	B2
Filing date	May 5, 2022
Priority date	Jan 11, 2017
Publication date	Jul 15, 2025
Grant date	Jul 15, 2025

Abstract

The present invention is related to compositions comprising clarified limulus amebocyte lysate (LAL), wherein the LAL is substantially free of coagulogen and methods of making such compositions. The invention further relates to a method of detecting an endotoxin in a sample using a chromogenic assay, the method comprising: (a) contacting the sample with a reagent comprising clarified LAL and a chromogenic substrate; and (b) measuring a chromogenic effect resulting from a change in the chromogenic substrate in the presence of endotoxin in the sample, wherein the LAL is substantially free of coagulogen. The invention also relates to kits comprising clarified LAL substantially free of coagulogen, and methods of making such.

First claim

What is claimed is:

1. A composition comprising clarified limulus amebocyte lysate (LAL) and a detergent, wherein the clarified LAL is LAL that has been (i) filtered using tangential flow filtration with a 20 kDa to 50 kDa filter to remove at least 60% (wt/wt) of its coagulogen such that it comprises less than 10% (wt/wt) of coagulogen relative to total protein in the LAL as measured by SDS-PAGE and protein stain, and then (ii) subjected to centrifugation.

2. The composition of claim 1 , further comprising a buffer, wherein the composition comprises 30% to 60% (v/v) the clarified LAL.

3. The composition of claim 2 , wherein the buffer is at a concentration of about 25 mM to about 50 mM.

4. The composition of claim 1 , wherein the detergent is a zwitterionic detergent.

5. The composition of claim 1 , wherein the detergent is at a concentration of about 0.002% to about 0.02%.

6. The composition claim 1 , wherein the composition comprises about 50% the clarified LAL.

7. The composition of claim 1 , further comprising a chromogenic substrate.

8. The composition of claim 7 , wherein the chromogenic substrate is Ac-Ile-Glu-Ala-Arg-pNA.

9. The composition of claim 7 , wherein the chromogenic substrate is at a concentration of about 0.11 mg/mL to about 0.77 mg/mL.

10. The composition of claim 1 , wherein the composition is lyophilized, or wherein the composition is in an aqueous solution.

11. The composition of claim 1 , wherein the clarified LAL comprises less than 5% (wt/wt) of coagulogen relative to total protein in the LAL as measured by SDS-PAGE and protein stain.

12. The composition of claim 1 , wherein the clarified LAL comprises less than 5 μg/μL coagulogen.

13. The composition of claim 1 , wherein the centrifugation is at greater than 1800 g for greater than 3 minutes.

14. The composition of claim 1 , wherein the composition is capable of detecting endotoxin at a sensitivity of about 0.005 EU/mL or less.

15. A composition comprising
a. the composition of claim 1 ,
b. a buffer, and
c. a chromogenic substrate,
wherein the composition comprises 30% to 50% the clarified LAL (v/v) and 10% to 30% (v/v) the chromogenic substrate.

16. The compositions of claim 15 , wherein the composition comprises 35% to 45% the clarified LAL and 15% to 25% the chromogenic substrate.

17. The composition of claim 15 , wherein the composition comprises 40% the clarified LAL and 20% the chromogenic substrate.

18. A composition comprising clarified limulus amebocyte lysate (LAL) and a detergent, wherein the clarified LAL comprises less than 5% (wt/wt) of coagulogen relative to total protein in the LAL as measured by SDS-PAGE and protein stain, and wherein the clarified LAL is made by a method comprising:
a. obtaining a solution derived from lysed amebocytes from Limulus polyphemus;
b. combining the solution from (a) with a buffer;
c. subjecting the combination from (b) to continuous tangential flow filtration (TFF) using a 20 kDa to 50 kDa membrane filter to produce a retentate; and
d. centrifuging the retentate from (c) at greater than 20,000×g for greater than 25 minutes to produce a supernatant, wherein the supernatant is the clarified LAL.

19. A kit comprising:
a. a composition comprising clarified limulus amebocyte lysate (LAL) and a detergent, wherein the clarified LAL has been (i) filtered using tangential flow filtration with a 20 kDa to 50 kDa filter to remove at least 60% (wt/wt) of its coagulogen such that it comprises less than 10% (wt/wt) of coagulogen relative to total protein in the LAL as measured by SDS-PAGE and protein stain, and then (ii) subjected to centrifugation,
b. a chromogenic substrate; and
c. instructions for detecting an endotoxin using the composition and the chromogenic substrate.

20. The kit of claim 19 , wherein the clarified LAL is lyophilized; or wherein the clarified LAL is in an aqueous solution.

Assignees

• Lonza Walkersville Inc

Inventors

• Stumbaugh Candice
• Tadesse Leben
• Lin Karen

Classifications

• G01N33/579 Primary

  involving limulus lysate · CPC title

• G01N2400/50

  Lipopolysaccharides; LPS · CPC title

• C12Q1/37 Primary

  involving peptidase or proteinase · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title